Header Logo

Connection

MICHAEL R MIGDEN to Middle Aged

Back to Details
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Middle Aged.
MICHAEL R MIGDEN
Connection Strength
0.250
Middle Aged
  1. Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas. Dermatol Surg. 2021 09 01; 47(9):1273-1275.
    View in: PubMed
    Score: 0.029
  2. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.029
  3. Severe pretibial myxedema refractory to systemic immunosuppressants. Cutis. 2019 Sep; 104(3):E1-E3.
    View in: PubMed
    Score: 0.025
  4. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
    View in: PubMed
    Score: 0.023
  5. Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol. 2018 Sep; 79(3):520-524.
    View in: PubMed
    Score: 0.023
  6. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
    View in: PubMed
    Score: 0.019
  7. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35(2):221-228.
    View in: PubMed
    Score: 0.008
  8. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol. 2023 06; 7:e2200490.
    View in: PubMed
    Score: 0.008
  9. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
    View in: PubMed
    Score: 0.007
  10. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.007
  11. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.007
  12. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.006
  13. Linear terra firma-forme dermatosis of the midline back. Cutis. 2018 Mar; 101(3):205-206.
    View in: PubMed
    Score: 0.006
  14. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
    View in: PubMed
    Score: 0.006
  15. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
    View in: PubMed
    Score: 0.006
  16. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
    View in: PubMed
    Score: 0.005
  17. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120.
    View in: PubMed
    Score: 0.005
  18. Phototherapeutic keratectomy for corneal scars. Ophthalmic Surg Lasers. 1996 May; 27(5 Suppl):S503-7.
    View in: PubMed
    Score: 0.005
  19. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
    View in: PubMed
    Score: 0.005
  20. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
    View in: PubMed
    Score: 0.005
  21. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.
    View in: PubMed
    Score: 0.005
  22. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003.
    View in: PubMed
    Score: 0.004
  23. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol. 2013 Jul; 52(7):856-61.
    View in: PubMed
    Score: 0.004
  24. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.